June 2021—Roche and GenMark Diagnostics have entered into a definitive merger agreement for Roche to acquire GenMark for about $1.8 billion on a fully diluted basis. GenMark’s syndromic panel testing portfolio will complement Roche’s molecular diagnostics portfolio, and Roche’s global network will enable expanded reach for GenMark’s products.
The transaction is expected to close in the second quarter of 2021 and is subject to customary closing conditions. GenMark’s principal operations will continue at its current location in Carlsbad, Calif.
Roche, 317-521-2000
GenMark Diagnostics, 760-448-4300